Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in Kidney Disease.

Jeffrey T HaSwapnil HiremathMin JunSuetonia C GreenDavid C WheelerDaniel W CoyneVlado PerkovicSunil V Badve

Published in: NEJM evidence (2024)

There was no evidence of a difference in the long-term cardiovascular safety profile of HIF prolyl hydroxylase inhibitors and ESA in adults with dialysis-dependent CKD and adults with nondialysis-dependent CKD. (PROSPERO registration number, CRD42021278011.).

Keyphrases

chronic kidney disease
end stage renal disease
endothelial cells